John David Konda
- f502-c003 Dottorato in Medicina Molecolare
- Dottorato: 27° ciclo
- Matricola: 759061
Contatti
- john.konda@studenti.unito.it
- Institute for Cancer Research and Treatment Strada Provinciale 142 km 3,95 10060 Candiolo,Torino-Italy
- https://dott-mm.campusnet.unito.it/do/studenti.pl/Show?759061
- VCard contatti
- QRcode contatti
Supervisore
Maria Flavia Di RenzoTesi di dottorato
“HSP27 Silencing Sensitizes cells with oncogenic activation of MET, EGFR and BRAF to Inhibitors”
Attività di ricerca
“HSP27 Silencing Sensitizes cells with oncogenic activation of MET, EGFR and BRAF to Inhibitors”- Studying the role of HSP27 in oncogene addicted cells .
Daniele Musiani, John David Konda, Simona Pavan, Erica Torchiaro,Francesco Sassi, Alessio Noghero, Jessica Erriquez, Timothy Perera,Martina Olivero,Maria Flavia Di Renzo"Heat-shock protein 27 (HSP27,HSPB1) is up-regulated by MET Kinase inhibitors and confers resistance to MET-targeted therapy FASEB J. 2014 Sep;28(9):4055-67
- May 9–12 2012 AACR Special Conference on Molecularly Targeted Therapies: Mechanisms of Resistance San Diego, CA. Philadelphia (PA): AACR; Clin Cancer Res 2012;18(10 Suppl):Abstract number B42“Heat Shock Protein 27 (HSP27, HSPB1) is up-regulated by MET kinase inhibition and limits the effectiveness of inhibitors”
- Oct 19-23 2013 AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics Boston, MA. Philadelphia (PA): AACR; Mol Cancer Therapeutics 2013;12(11 Suppl):Abstract number C131“HSP27 is necessary in cells showing oncogene hyper-activation”
2013 Boston Massachusetts, USA, 19-23 Oct “AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference”.
2014 Candiolo Turin, Italy, 4-5 Oct
IRCC International Conference - “Molecular Clinical Oncology 'Precision Medicine'”
2015 MBC Turin, Italy, 18-20 Feb "Frontiers in Regenerative Medicine"
2015 Candiolo Turin, Italy, 6-7 Jun
IRCC International Conference - “Molecular Oncology from Signal Transduction to Cancer Precision Medicine'”
2012
1) Dr. Laura Soucek PhD "Pre-clinical validation of Myc as a target in cancer therapy" Friday 3 February 2012
2) Prof. Fortunato Ciardiello "Molecular targeted therapies in metastatic colorectal cancer" Friday 10 February 2012
3) Dr. Manuel Hidalgo Pancreatic Cancer: From Molecular Understanding to Personalized Treatment. Friday 13 April 2012
4) Prof. Michael Clague Receptor trafficking and signaling: governance by ubiquitin and phosphorylation. Friday 20 April 2012
5) Dr. Riccardo Dalla Favera "The Genome of Diffuse Large B-Cell Lymphoma" Monday 7 May 2012
6) Prof. Stefan Offermanns "Novel roles of B-plexins and GPCRs in tumour cell metastasis" Friday 18 May 2012
7) Prof. Dr. Amparo Acker-Palmer "Mechanisms of tumor invasion and evasive resistance to anti-angiogenesis therapy" Friday 25 May 2012
8) Prof. David Sidransky Markers and Models to personalize cancer therapy Thursday 26 July 2012
9) Prof. Michael Simons "VEGF receptor trafficking and signaling." Friday 12 October 2012
10) Annarosa Leri Cardiac Stem Cells and Myocardial Regeneration Friday 26 October 2012
2013
11) Patrick Mehlen "The dependence receptor notion: from a cell biology paradigm to alternative targeted cancer therapies" Friday 1 February 2013
12) Dr. Michele Milella Beyond single pathway inhibition: MEK inhibition-based vertical and lateral combination strategies to achieve synergistic anti-tumor activity Friday 15 March 2013
13) Patrick Caswell Integrins and endocytic trafficking in the regulation of intracellular signaling Monday 18 March 2013
14) Dr. Ion Cristian Cirstea RAS GTPases germline mutations lead to dysregulated signaling and developmental disorders Thursday 4 April 2013
15) Dr. Maria Comanescu and Prof. Giovanni Bussolati Triple negative breast cancers Friday 24 May 2013
16) Pete Smith Challenges in translating the cancer genome into impactful drugs Wednesday 19 June 2013
17) Tim Maughan Molecular selection of therapy in advanced colorectal cancer - building the platforms in clinic and laboratory Tuesday 25 June 2013
18) Caroline Dive Circulating Tumour Cells,as Biomarkers and for Exploring Biology Wednesday 24 July 2013
19) Yardena Samuels Mutational and Functional analysis of melanoma-filling in the gap Thursday 17 October 2013
20) Ivana Bozic Dynamics of Targeted Cancer Therapy Thursday 14 November 2013
2014
21) Dr. Giovanni Germano Role of Macrophage targeting in the anti-tumor activity of Trabectedin Friday 7 February 2014
22) Prof. Paola Chiarugi Reciprocal metabolic deregulation of tumors and their stroma: a new druggable synergy Thursday 27 February 2014
23) Prof. Julian Downward Mechanisms of transformation by RAS oncogenes: searching for novel therapeutic approaches Friday 28 February 2014
24) Lisa Ryden Lund University, Clinical Sciences, Department of Surgery
Diagnosis of tumor progression in the clinical setting Tuesday 1 April 2014
25) Prof. Carlos Caldas Molecular stratification and molecular monitoring in breast cancer Wednesday 30 April 2014
26) Prof. Alexander Eggermont Spectacular Advances in Drug Development: Melanoma as Model System for both Targeted and Immunotherapeutic Approaches Thursday 12 June 2014
27) Prof. Alexander Eggermont Spectacular Advances in Drug Development: Melanoma as Model System for both Targeted and Immunotherapeutic Approaches Thursday 12 June 2014
28) Prof. Alain Thierry Multimarker analysis of circulating cell-free DNA toward personalized medicine for colorectal cancer Thursday 10 July 2014
29) Dr. Margaret Foti, PhD, MD Reflections on the Global Cancer Research Landscape Tuesday 25 November 2014
2015
30) Dr. Jan Paul Medema “Colon cancer stem cell resistance to therapy” January 26th 2015
31) Dr Nicola Normanno "Tumor heterogeneity in colon cancer: therapeutic implications" at Candiolo Cancer Institute, January 26th 2015
32) Dr. Marc Reymond “Laparoscopic Intraperitoneal Chemotherapy: Cancer under Pressure” March 16th 2015
33) Prof. Francesca Ciccarelli "Tumor clonal expansion and impact on treatment selection" Candiolo, May 4th 2015
34) D-day 2015 della Scuola di Dottorato in Scienze della Vita e della Salute "Aula Magna" at Rettorato dell'Università di Torino, September 16th 2015
35) Prof. Ruggero De Maria " Therapeutic strategies on cancer stem cell targeting" Candiolo Cancer Institute , October 2th 2015
11 October 2012, IRCC, Candiolo. "Must most metastatic cancer remain "incurable"?". James Dewey Watson, Nobel Prize Cold Spring Harbor Laboratory (USA)